Neurological diseases cause a massive burden, which will increase as populations age. Rapid advances in our understanding of disease mechanisms must be translated into human benefits. We cannot stop once technologies have been developed, but must ensure that evidence and pipelines are in place for their implementation to reduce burden and inequalities.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Deuschl, G. et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health 5, e551–e567 (2020).
Cooksey, D. A Review of UK Health Research Funding https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/228984/0118404881.pdf (HM Treasury, 2006).
Stowe, R. L. et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst. Rev. 2, CD006564 (2008).
Lattanzi, S. et al. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs 34, 1105–1120 (2020).
Taylor, C. et al. Care in Europe after presenting to the emergency department with a seizure; position paper and insights from the European Audit of Seizure Management in Hospitals. Eur. J. Neurol. 29, 1873–1884 (2020).
Hillmann, S. et al. Temporal changes in the quality of acute stroke care in five national audits across Europe. BioMed Res. Int. 2015, 432497 (2015).
Kirkham, J. J. et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations. PLoS Med. 14, e1002447 (2017).
Reinhard, C. et al. The European reference network for rare neurological diseases. Front. Neurol. 11, 616569 (2021).
Epi25 Collaborative. Sub-genic intolerance, ClinVar, and the epilepsies: a whole-exome sequencing study of 29,165 individuals. Am. J. Hum. Genet. 108, 2024 (2021).
National Institute for Health and Clinical Excellence. Diagnostics Assessment Programme Manual https://www.nice.org.uk/media/default/about/what-we-do/nice-guidance/nice-diagnostics-guidance/diagnostics-assessment-programme-manual.pdf (NICE, 2011).
Acknowledgements
A.G.M. is a National Institute for Health Research (NIHR) Senior Investigator and also part funded by NIHR ARC North West Coast. The views expressed in this article are those of the author and not necessarily those of the NIHR or the Department of Health and Social Care.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Marson, A.G. The importance of getting evidence into practice. Nat Rev Neurol 18, 443–444 (2022). https://doi.org/10.1038/s41582-022-00689-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00689-8
